Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
bioMerieux ( (FR:BIM) ) has provided an announcement.
bioMérieux announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, where its CEO, Pierre Boulud, will outline the company’s strategic plan, GO•28, aiming for sustainable growth and improved margins by 2028. The presentation will highlight recent advancements, including the installation of BIOFIRE® and SPOTFIRE® units and the acquisition of SpinChip, enhancing bioMérieux’s position in the point-of-care market.
More about bioMerieux
bioMérieux is a global leader in the in vitro diagnostics industry, with a presence in 45 countries and serving over 160 countries through a vast network of distributors. The company offers diagnostic solutions including systems, reagents, software, and services, primarily used for diagnosing infectious diseases and detecting microorganisms in various products. In 2023, bioMérieux reported revenues of €3.7 billion, with a substantial portion of sales outside France. The company is listed on the Euronext Paris stock market.
YTD Price Performance: 3.53%
Average Trading Volume: 45,990
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: €12.55B
Find detailed analytics on BIM stock on TipRanks’ Stock Analysis page.
